Thyroid Supplementation

Verify with FDA CVM →

27 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
27
Total Reports
5
Deaths Reported
1850.0%
Death Rate

Active Ingredients

Thyroid Supplementation

Administration Routes

OralUnknown

Species Affected

Dog 26
Cat 1

Most Affected Breeds

Crossbred Canine/dog 5
Chihuahua 4
Dog (other) 3
Beagle 3
Retriever - Golden 2
Doberman Pinscher 2
Retriever - Labrador 2
Maltese 1
Boxer (German Boxer) 1
Bulldog 1

Most Reported Reactions

Underdose 5
Elevated serum alkaline phosphatase (SAP) 5
Elevated alanine aminotransferase (ALT) 5
Malaise 4
Death by euthanasia 3
Weight loss 3
Polyuria 3
Muscle weakness NOS 3
Lethargy (see also Central nervous system depression in Neurological) 3
Lethargy (see also Central nervous system depression in 'Neurological') 2
Diarrhoea 2
Panting 2

Outcome Breakdown

Outcome Unknown
11 (40.7%)
Recovered/Normal
6 (22.2%)
Ongoing
5 (18.5%)
Euthanized
3 (11.1%)
Died
2 (7.4%)

Data Summary

Metric Value
Total adverse event reports 27
Reports involving death 5
Case-fatality rate (reported events) 1850.0%
Distinct species in reports 2
Distinct breeds in reports 13
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Thyroid Supplementation Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 27 adverse event reports referencing Thyroid Supplementation, including 5 reports in which the animal died — a 1850.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Thyroid Supplementation. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Thyroid Supplementation reports are Dog (26 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (5), Chihuahua (4), Dog (other) (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Thyroid Supplementation are Underdose (5), Elevated serum alkaline phosphatase (SAP) (5), Elevated alanine aminotransferase (ALT) (5), Malaise (4). Of the 27 reports with a coded outcome, Outcome Unknown is the leading category at 40.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Thyroid Supplementation.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial